
Improving conventional prognosticators in diffuse large B cell lymphoma using marker ratios

Kim-Anh LÊ CAO

NHMRC Career Development Fellow, Statistician

*The University of Queensland Diamantina Institute
Translational Research Institute
Brisbane, Queensland, Australia*




DIFFUSE LARGE B-CELL LYMPHOMA

- Incidence of lymphoma more than doubled in last 20 years
- 6th most common cancer
- Risk by age 85yo of Non Hodgkin's Lymphoma (NHL) is 1 in 42
- DLBCL is most common subtype in adults (30-40% of all cases in Australia) and is the most aggressive form of NHL

Biggest risk factor (by far) is **impaired immunity**

TREATMENTS AND SURVIVAL

Of the majority of patients that die from DLBCL, 30-40% will do so within 2 yrs despite chemotherapy




- Addition of **Rituximab** to combination chemotherapy CHOP improves survival in DLBCL by 10-15%
- Exposure to R-CHOP induce chemo-resistance and toxicity in certain group of patients
- Need to more accurately predict response to R-CHOP to **stratify patients** and **identify new immune target agents**

WHY DO PRE TREATMENT PROGNOSTICATORS FAIL?

Cell of Origin (COO), international prognostic index (IPI) and i-PET/CT still fail to identify patients that will relapse

Tumour microenvironment (TME) contributes to tumour initiation, progression and responses to therapy

Three players in TME:



⇒ need to understand **interaction of malignant B cell and anti-tumour immune response** using **gene expression**

IMMUNOMODULATION IN TUMOURS: AN ITALIAN SPAGHETTI FILM

Immune effectors **drive potent anti-tumour responses**

Tumour cells produce host-checkpoint responses: dampen immune-effectors, induce **immunosuppressive microenvironment**


In solid-organ cancers, tumor biopsies display 'adaptive resistance'.

Is it also the case in DLBCL?

Creative idea from Prof. Maher Gandhi



A FINE BALANCE BETWEEN IMMUNE EFFECTORS AND CHECKPOINTS TO PREDICT OUTCOME?



Hypothesis:

The relative composition of antagonist checkpoints and immune effectors is prognostic to DLBCL

Does the **ratio of Immune Effector(s) / Checkpoint(s)** predict outcome?

DATA

Nanostring™ digital multiplex gene expression (Discovery data)

- 158 de novo DLBCL treated with R-CHOP from 2 Australian centres (Brisbane, Canberra)
- Formalin-fixed paraffin embedded tissue (FFPET) + survival outcome
- Median follow up: 4 yrs; Median age: 62 (27-86)

Affymetrix gene expression (Validation data)

- 233 patients treated with R-CHOP
- Fresh-frozen samples + survival outcome
- Median follow up: 2.8 yrs;
- Publicly available data (GSE10846*)

*Lenz, G., et al. (2008), *Stromal gene signatures in large-B-cell lymphomas*. New England Journal of Medicine. **359** (22)

GENE EXPRESSION RATIOS

Investigating a fine balance between immune effectors and check points

- Immune-Effectors in **numerator**: CD4, CD8, CD56 and CD137
- Immune-Checkpoints in **denominator**: CD163, CD68, **M2 (CD163/CD68)**, PD1 and **PDL1**

Various combinations of gene expression ratios assessed:

1. Individual gene markers (total: 10)
2. Simple ratio (1 gene / 1 gene, total: 12 ratios)
3. All possible combinations of numerator and denominator (total: 44 ratios)

ANALYTICAL CHALLENGES

Use of gene ratios to stratify survival outcome has been successful in some cancer studies but limitations


- **Define optimal cut-off ratio to segregate good and poor outcomes:** median is not satisfying as we expect ~30% mortality
- Assess all possible ratio combinations in an efficient way

Our aims

- Identify the most robust gene ratio among our gene candidates
- Determine optimal cut-off with appropriate statistical method
- Validate results in external cohort

C Keane, K-A. Lê Cao, et al. and MK Gandhi (2015). Ratios of T-cell immune-effectors with tumour associated macrophages and PD-1/PD-L1 axis immune-checkpoint molecules, add to the predictive power of conventional prognosticators in diffuse large B cell lymphoma. *Lancet Haematology (08/2015)*


SEE THE FOREST FOR THE TREES




P. KLAMMER

Tree-based survival models

- **Input:** gene expression ratio and survival outcome
- **Output:** stratify high vs. low risk patients with optimal ratio cut-off ('best split') based on entropy criterion



BEST SPLIT IN SURVIVAL TREE



Segregation rule based on patient partitioning for each ratio

- If ratio value \leq best split, then patient classified as 'high risk' (LHS of tree)
- If ratio value $>$ best split, then patient classified as 'low risk' (RHS of tree)


Discovery cohort (Nanostring)

- log rank test to assess differences btw the two survival curves obtained from tree + correction for multiple testing.

Test cohort (Affymetrix)

- Apply same split as in discovery data set, log rank test + correction for multiple testing.

ASSESSING VARIOUS COMBINATIONS



Single markers

- e.g. CD163, CD68, $p = 1$

Simple ratio

- e.g. M2 = CD163/CD68, $p = 0.0056$


← **Best combination identified with tree-based survival model**

- $(CD4 \times CD8) / (M2 \times PD-L1)$, $p < 0.0001$
- best split = -0.279

OUR IMMUNE RATIO ADDS TO CONVENTIONAL PROGNOSTICATORS


Cell of origin (COO) classifies

- germinal centre B-cell (GCB)
- non-GCB




GCB +
immune ratio


nGCB +
immune ratio



40% of
patients
in high risk
identified



VALIDATION IN EXTERNAL COHORT



Affymetrix gene expression study

1. Calculate our immune ratio $(CD4 \times CD8)/(M2 \times PD-L1)$
 2. Set up our best split -0.279
 3. Apply our segregation rule
- ~60% of patients assigned to high risk
 - Multivariate Cox regression confirms immune ratio is independent from prognosticators COO and IPI

WHAT IF WE HAD USED A MEDIAN CUT-OFF?

# ratios with $p \leq 0.05$ (log rank test)	Median cut-off	Survival tree cut-off
Discovery Nanostring	21	54
Validation Affymetrix	0	4

Further work / Discussion

- fresh vs. frozen samples have an influence on validation
- improve results with a confidence interval for best split
- not shown: experimental validation successful in on a 3rd cohort
(n = 160, flow cytometry and i-PET/CT outcome)

CONCLUSIONS

Our **immune ratio**

- Based on biological hypothesis
- Complements conventional prognosticators
- Identifies 40% of patients with poor outcome
- Validation in two external cohorts
- May help identify better target drugs (e.g. PDL-1) for patients not responding to R-CHOP. Clinical trial? (patent submitted).

Ratios for big data? and my (statistician) point of view

- Address the issue of platform variability
- Combination of genes vs. single gene biomarker approach is beneficial
- Could be expanded to other cancer studies genomewide

ACKNOWLEDGMENTS



Prof M Gandhi lab incl. &

- Maher Gandhi
- Colm Keane
- Erica Han
- Dipti Talaulikar



Australian Government
National Health and
Medical Research Council

Lê Cao group

Statisticians

- Florian Rohart
- Ian Hughes
- [insert_your_name_here*](#)

PhD students

- Ralph Patrick
- Chao Liu
- Jasmin Straube
- Amrit Singh
- Thom Cuddihy
- Aimee Hanson

Bioinf Masters student

- Vanessa Lakis

[*we are hiring! UQjobs #498081](#)